Since the COVID-19 pandemic, the healthcare sector has seen a significant increase in its revenues. Due to the continued spread of the disease and an increasing number of people living longer, healthcare services demand is likely to continue growing. Therefore, we think healthcare stocks Johnson & Johnson (JNJ), Abbott (ABT), Anthem (ANTM), and Biogen (BIIB), which have each recently reported better-than-expected earnings results, could be ideal bets now. Keep reading. Solid third-quarter corporate earnings have led to steady gains in benchmark stock indices. Dow Jones was up for the third day straight to set another record, October 26. The S&P 500 also rose to fresh highs that day. According to CNBC, 80% of S&P 500 companies that have reported earnings so far have beaten Wall Street expectations.

Since the outbreak, healthcare has been the center of attention. Biotech and pharmaceutical companies have already generated billions of dollars through vaccines and COVID-19 treatments. Telehealth is also gaining popularity. They report a nearly doubling in visits to digital healthcare for 2020. This space is likely to see more investment due to the growing popularity and robust use of digital health. FactSet reports that companies with a greater international exposure will likely experience higher earnings growth. Companies that generate more than half of their sales in the United States have a 44.3% blended earnings growth rate, while companies with less than 50% sales within the United States experience a 26.3% earnings increase rate.

Johnson & Johnson (JNJ), Abbott Laboratories (NYSE:), Anthem, Inc.(ANTM) and Biogen Inc. [NASDAQ:] have all reported stronger than expected earnings results. So, considering their fundamental strength, we think these stocks could be solid additions to cash in on the industry’s growth.

Continue reading on StockNews